PHREESIA REPORTS Q4 NET INCOME OF USD 1.295 MILLION
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Source: moomoo
- Company Overview: PHR EESIA reported a net income of USD 1.295 million for Q4.
- Financial Performance: The financial results indicate a positive performance in the fourth quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.350
Low
24.00
Averages
29.09
High
35.00
Current: 9.350
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Commvault and Others Under Shareholder Investigation
- Shareholder Investigations Initiated: Grabar Law Office is investigating Commvault Systems, Inc. for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- False Statement Allegations: A recently filed securities fraud class action alleges that Commvault misled investors with false and misleading statements regarding its projected ARR growth for fiscal year 2026, leading to significant investor misconceptions about the company's prospects.
- Similar Issues at LKQ: Grabar Law Office is also investigating LKQ Corporation, where executives allegedly failed to disclose critical information about customer losses and declining market share related to the acquisition of Uni-Select, resulting in investor misjudgments about financial health.
- Phreesia's Financial Transparency Questioned: Phreesia, Inc. is under scrutiny for allegedly failing to disclose slowing demand and diminished visibility into revenue streams, which could undermine investor confidence in the company's future performance.
See More
Phreesia Faces Class Action Lawsuit from Shareholders
- Stock Price Plunge: Phreesia's shares dropped 27% after the company revised its fiscal 2027 revenue guidance down from $545 million to a range of $510 million to $520 million, resulting in a loss of $3.03 per share, which severely undermines investor confidence and may impact future financing capabilities.
- Revenue Projection Errors: The lawsuit alleges that Phreesia faced deteriorating visibility into pharmaceutical manufacturers' spending commitments when it issued its fiscal 2027 revenue projections in December 2025, raising doubts about the company's future growth and potentially affecting its market position.
- Declining Pharmaceutical Commitments: Phreesia's Network Solutions segment heavily relied on seasonal spending commitments from pharmaceutical manufacturers, yet management's statements in May and December 2025 were deemed misleading as clients were already reducing spending, which could jeopardize the company's revenue stability.
- Legal Accountability Issues: This lawsuit raises significant questions regarding revenue projection disclosure obligations in the healthcare technology sector, emphasizing that investors are entitled to know the authenticity of spending commitments to make informed investment decisions, potentially leading to improvements in the company's transparency.
See More
Phreesia Shares Plunge 27% Following Revenue Guidance Cut
- Stock Plunge: Phreesia's corrective disclosure on March 30, 2026, led to a 27% drop in share price, losing $3.03 per share from $11.41 to $8.38, indicating a significant loss of market confidence in the company's future revenue.
- Revenue Guidance Cut: The company revised its fiscal 2027 revenue outlook down from $545-$559 million to $510-$520 million, citing lower-than-expected spending from pharmaceutical clients, which highlights deteriorating visibility in its Network Solutions segment.
- Lawsuit Allegations: A class action lawsuit claims that Phreesia's executives assured investors of consistent revenue visibility throughout the class period, despite weakening commitments from pharmaceutical clients, potentially leading to substantial investor losses.
- Market Reaction: The disclosure revealed Phreesia's heavy reliance on pharmaceutical marketing budgets within its Network Solutions segment, and the market's repricing of shares illustrates the sensitivity to the gap between internal knowledge and external communication.
See More
Phreesia Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Phreesia, alleging securities fraud and other unlawful business practices by the company and certain officers, which could expose the company to significant legal risks and diminish investor confidence.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a substantial reduction in its revenue growth projections for fiscal year 2027, attributing this shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, which may adversely affect its future financial performance.
- Stock Price Plunge: Following the revenue guidance cut, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, indicating market concerns regarding the company's outlook and operational stability.
- Investor Action Deadline: Investors are advised to apply to be the Lead Plaintiff in the class action by July 13, 2026, if they purchased Phreesia securities during the class period, as this could impact their rights to claim damages in the lawsuit.
See More
Phreesia Class Action Lawsuit Notification
- Class Action Notification: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing weakened pharmaceutical marketing commitments in its Network Solutions segment, which led to investor losses when the truth emerged, indicating a slowdown in demand and reduced visibility in key revenue streams.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and was ranked No. 1 by ISS Securities Class Action Services in 2017, consistently ranking in the top four since 2013, and recovering over $438 million for investors in 2019 alone, showcasing its strong track record in this field.
- Investor Advisory: Investors are advised to choose legal counsel carefully; Rosen Law Firm recommends selecting attorneys with proven success in securities class actions to avoid partnering with firms that merely act as intermediaries, ensuring effective protection of their rights.
See More
Phreesia Shareholder Class Action Notice
- Lawsuit Background: The Gross Law Firm has issued a notice to shareholders of Phreesia, Inc. (NYSE:PHR), encouraging those who purchased shares during the class period from May 8, 2025, to March 30, 2026, to contact the firm regarding potential lead plaintiff appointment.
- Allegations: The complaint alleges that Phreesia misled investors by providing overly positive statements while concealing significant adverse facts about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment.
- Financial Impact: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, resulting in a stock price decline from $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, a drop of approximately 27%.
- Shareholder Next Steps: Shareholders must register for the class action by July 13, 2026, and upon registration, they will receive updates throughout the case lifecycle, with no cost or obligation to participate.
See More
Commvault and Others Under Shareholder Investigation
- Shareholder Investigations Initiated: Grabar Law Office is investigating Commvault Systems, Inc. for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- False Statement Allegations: A recently filed securities fraud class action alleges that Commvault misled investors with false and misleading statements regarding its projected ARR growth for fiscal year 2026, leading to significant investor misconceptions about the company's prospects.
- Similar Issues at LKQ: Grabar Law Office is also investigating LKQ Corporation, where executives allegedly failed to disclose critical information about customer losses and declining market share related to the acquisition of Uni-Select, resulting in investor misjudgments about financial health.
- Phreesia's Financial Transparency Questioned: Phreesia, Inc. is under scrutiny for allegedly failing to disclose slowing demand and diminished visibility into revenue streams, which could undermine investor confidence in the company's future performance.
See More
Phreesia Faces Class Action Lawsuit from Shareholders
- Stock Price Plunge: Phreesia's shares dropped 27% after the company revised its fiscal 2027 revenue guidance down from $545 million to a range of $510 million to $520 million, resulting in a loss of $3.03 per share, which severely undermines investor confidence and may impact future financing capabilities.
- Revenue Projection Errors: The lawsuit alleges that Phreesia faced deteriorating visibility into pharmaceutical manufacturers' spending commitments when it issued its fiscal 2027 revenue projections in December 2025, raising doubts about the company's future growth and potentially affecting its market position.
- Declining Pharmaceutical Commitments: Phreesia's Network Solutions segment heavily relied on seasonal spending commitments from pharmaceutical manufacturers, yet management's statements in May and December 2025 were deemed misleading as clients were already reducing spending, which could jeopardize the company's revenue stability.
- Legal Accountability Issues: This lawsuit raises significant questions regarding revenue projection disclosure obligations in the healthcare technology sector, emphasizing that investors are entitled to know the authenticity of spending commitments to make informed investment decisions, potentially leading to improvements in the company's transparency.
See More
Phreesia Shares Plunge 27% Following Revenue Guidance Cut
- Stock Plunge: Phreesia's corrective disclosure on March 30, 2026, led to a 27% drop in share price, losing $3.03 per share from $11.41 to $8.38, indicating a significant loss of market confidence in the company's future revenue.
- Revenue Guidance Cut: The company revised its fiscal 2027 revenue outlook down from $545-$559 million to $510-$520 million, citing lower-than-expected spending from pharmaceutical clients, which highlights deteriorating visibility in its Network Solutions segment.
- Lawsuit Allegations: A class action lawsuit claims that Phreesia's executives assured investors of consistent revenue visibility throughout the class period, despite weakening commitments from pharmaceutical clients, potentially leading to substantial investor losses.
- Market Reaction: The disclosure revealed Phreesia's heavy reliance on pharmaceutical marketing budgets within its Network Solutions segment, and the market's repricing of shares illustrates the sensitivity to the gap between internal knowledge and external communication.
See More
Phreesia Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Phreesia, alleging securities fraud and other unlawful business practices by the company and certain officers, which could expose the company to significant legal risks and diminish investor confidence.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a substantial reduction in its revenue growth projections for fiscal year 2027, attributing this shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, which may adversely affect its future financial performance.
- Stock Price Plunge: Following the revenue guidance cut, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, indicating market concerns regarding the company's outlook and operational stability.
- Investor Action Deadline: Investors are advised to apply to be the Lead Plaintiff in the class action by July 13, 2026, if they purchased Phreesia securities during the class period, as this could impact their rights to claim damages in the lawsuit.
See More
Phreesia Class Action Lawsuit Notification
- Class Action Notification: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing weakened pharmaceutical marketing commitments in its Network Solutions segment, which led to investor losses when the truth emerged, indicating a slowdown in demand and reduced visibility in key revenue streams.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and was ranked No. 1 by ISS Securities Class Action Services in 2017, consistently ranking in the top four since 2013, and recovering over $438 million for investors in 2019 alone, showcasing its strong track record in this field.
- Investor Advisory: Investors are advised to choose legal counsel carefully; Rosen Law Firm recommends selecting attorneys with proven success in securities class actions to avoid partnering with firms that merely act as intermediaries, ensuring effective protection of their rights.
See More
Phreesia Shareholder Class Action Notice
- Lawsuit Background: The Gross Law Firm has issued a notice to shareholders of Phreesia, Inc. (NYSE:PHR), encouraging those who purchased shares during the class period from May 8, 2025, to March 30, 2026, to contact the firm regarding potential lead plaintiff appointment.
- Allegations: The complaint alleges that Phreesia misled investors by providing overly positive statements while concealing significant adverse facts about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment.
- Financial Impact: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, resulting in a stock price decline from $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, a drop of approximately 27%.
- Shareholder Next Steps: Shareholders must register for the class action by July 13, 2026, and upon registration, they will receive updates throughout the case lifecycle, with no cost or obligation to participate.
See More
